Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"UK industry needs 0.25% cut in interest rates":

This article was originally published in Clinica

Executive Summary

UK industry needs a 0.25% cut in interest rates, says the Trades Union Congress (TUC), the manufacturing and services sectors' main representative body, in order to encourage investment. Its calls come despite relatively positive GDP data that puts overall output growth at around 1.9%. Although this is in line with treasury predictions, temporarily easing the pressure on increased investment, manufacturing continues to suffer, says the TUC. "Manufacturing output is contracting by around 6% annually," Ian Brinkley, TUC senior economist, told Clinica. Although the overall economy is buoyed by 3.6% growth in the services industry, it remains below the long-term average for the UK. The Association of British Health-Care Industries (ABHI) has echoed these concerns, particularly in view of the strength of sterling (see Clinica No 991, p 7). The TUC is due to publish its budget submission on February 11 and discuss it at its pre-budget conference on February 28.

You may also be interested in...

FDA’s Follow-Up Sunscreen Trial Shows More Of The Same: Absorption Of All Tested UV Filters

The FDA emphasizes that findings from its second, more extensive clinical study on the absorption potential of sunscreen active ingredients are not in themselves signals that the UV filters are unsafe. However, they portend heavy work ahead for industry if the ingredients are to remain GRASE and available for use in OTC sunscreen drug products stateside.  

Health Sector On High Alert As Wuhan Coronavirus Spreads

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts